BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023
November 09, 2023 at 09:05 pm
Share
BIOLASE, Inc. provided earnings guidance for the fourth quarter and full year of 2023. The company currently expects full year 2023 revenue to be 1% to 3% higher than full year 2022 revenue. In addition, the Company expects net loss from operations for full year 2023 to be significantly improved compared to the comparable period for the prior year.
The Company expects net loss from operations for the fourth quarter of 2023 to be significantly improved compared to the comparable period for the prior year.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.